Question to the Department of Health and Social Care:

To ask His Majesty's Government what discussions they have held with the devolved nations regarding treatments and care for children diagnosed with alpha-1 antitrypsin deficiency.

Orphanet estimates of the prevalence if alpha-1 antitrypsin deficiency within Western Europe and the United States of America is between one in 1,600 and one in 5,000. No England specific estimates are available.

There have been no discussions specific to alpha-1 antitrypsin deficiency. The administrations of all four nations continue to work collaboratively to improve the lives of people living with genetic and rare conditions under the UK Rare Diseases Framework. The framework has recently been extended until January 2027.